Quick Answer
Intellia Therapeutics, Inc. reported Net Income of -$412.69 million for fiscal year 2025.
Intellia Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$412.69M | +20.5% |
| 2024 | -$519.02M | -7.9% |
| 2023 | -$481.19M | -1.5% |
| 2022 | -$474.19M | -77.0% |
| 2021 | -$267.89M | -99.6% |
| 2020 | -$134.23M | +71.7% |
| 2019 | -$474.19M | -455.6% |
| 2018 | -$85.34M | -26.4% |
| 2017 | -$67.54M | -113.5% |
| 2016 | -$31.63M | -155.2% |
| 2015 | -$12.40M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$101.32M | +25.3% | -0.1% |
| June 30, 2025 | -$101.25M | +31.1% | +11.4% |
| March 31, 2025 | -$114.33M | -6.4% | +15.8% |
| September 30, 2024 | -$135.71M | -11.0% | +7.7% |
| June 30, 2024 | -$146.97M | -18.8% | -36.8% |
| March 31, 2024 | -$107.44M | -4.2% | +12.1% |
| September 30, 2023 | -$122.22M | -7.9% | +1.2% |
| June 30, 2023 | -$123.68M | -22.8% | -19.9% |
- Intellia Therapeutics, Inc. showed an increase of +20.5% in Net Income compared to the prior fiscal year.
- Over the 2015–2025 period, Intellia Therapeutics, Inc.’s net income has declined by 3229.0% (from -$12.40 million to -$412.69 million).
- The most recent figure is from Intellia Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: